Rajiv Gandhi Cancer Institute and Research Centre | Clinical Research (Dr D.C.Doval)

Research site

(Unclaimed)

Location

D-18, Sector 5, Rohini, New Delhi, Delhi, India

Site insights

Top conditions

Top treatments

Pembrolizumab

PF-07220060

Tyrosine

Letrozole

LY3537982

Lorlatinib

Dacomitinib

Cetuximab

Docetaxel

Palbociclib

Parent organization

This site is a part of Rajiv Gandhi Cancer Institute and Research Centre

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 40 total trials

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (TRIlogy-5)

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Enrolling

Multiple Myeloma

Drug: Teclistamab

Drug: JNJ-79635322

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Pemetrexed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Pemetrexed

Drug: Carboplatin

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting

Neoplasms

Drug: Cetuximab

Drug: Oxaliplatin

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: Pemetrexed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Crizotinib

Drug: Repotrectinib

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Selpercatinib

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY1093)

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy...

Enrolling

Non-small Cell Lung Cancer

Drug: Relatlimab

Drug: Nivolumab

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment (ACCESS-1)

This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on peopl...

Active, not recruiting

Paroxysmal Nocturnal Hemoglobinuria

Drug: Pozelimab

Drug: Ravulizumab

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Active, not recruiting

Relapsed or Refractory Multiple Myeloma

Drug: Mezigdomide

Drug: Dexamethasone

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for th...

Enrolling

Metastatic Pancreatic Ductal Adenocarcinoma

Cachexia

Drug: placebo

Drug: ponsegromab

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Active, not recruiting

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

Locations recently updated

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-smal...

Enrolling

Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Cancer Metastatic

Drug: Docetaxel monotherapy

Drug: PF-08046054

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through th...

Active, not recruiting

Urothelial Carcinoma

Drug: cisplatin

Drug: carboplatin

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition...

Enrolling

Biliary Tract Cancer

Drug: Cisplatin

Drug: Gemcitabine

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Active, not recruiting

Myelodysplastic Syndromes

Biological: Epoetin Alfa

Biological: Luspatercept

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90...

Enrolling

Carcinoma, Squamous Cell

Drug: Cetuximab

Radiation: Radiation Therapy

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal gro...

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

Drug: H2 Receptor Antagonist

Drug: Dexamethasone (or equivalent)

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo comb...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Olomorasib

Drug: Placebo